Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bruun, L.
Right arrow Articles by Christensson, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruun, L.
Right arrow Articles by Christensson, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 598-602
© 2003 European Renal Association-European Dialysis and Transplant Association

Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment

Laila Bruun1,, Thomas Björk2, Hans Lilja3, Charlotte Becker3, Ove Gustafsson4 and Anders Christensson1

1 Department of Nephrology and Transplantation, 2 Department of Urology and 3 Department of Laboratory Medicine, University Hospital, Malmö and 4 Department of Urology, University Hospital, Huddinge, Sweden

Background. Men with chronic renal failure evaluated for transplantation are often tested for prostate specific antigen (PSA) to detect prostate cancer. PSA occurs in several different molecular forms in serum: free PSA (fPSA) and complexed PSA (cPSA), the sum of which corresponds to total PSA (tPSA). In addition to tPSA, percent fPSA to tPSA (%fPSA) is widely used to enhance discrimination of benign disorders from prostate cancer. The low molecular mass of fPSA suggests elimination by renal glomerular filtration and that renal failure may significantly influence %fPSA. We evaluated whether established reference levels for %fPSA are applicable also to patients treated with haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).

Methods. The study included 20 men on intermittent haemodialysis with low-flux membranes and 25 men on CAPD, without known history of prostate cancer. The control group included 3129 men without known prostate cancer. We analysed fPSA and tPSA in serum by dual-label immunofluorometric assays, from which we calculated %fPSA and cPSA. Serum levels of different PSA forms were adjusted for age and presented as geometric means.

Results. Percent fPSA was significantly higher in patients on either haemodialysis (39.5%) or CAPD (39.6%) compared with controls (28.1%). Haemodialysis patients, but not CAPD patients, had significantly higher mean levels of fPSA. Levels of tPSA and cPSA for haemodialysis or CAPD patients did not differ significantly compared with controls.

Conclusions. Recommended reference ranges for %fPSA, based on men with normal renal function, do not apply to uraemic men on dialysis. In these men, a high %fPSA should not be considered as a sign of benign disease. This is clinically important in the evaluation of dialysis patients for transplantation, as %fPSA is often used as a tool for detection of prostate cancer.

Keywords: haemodialysis; peritoneal dialysis; prostate cancer; PSA; renal failure; renal transplantation

Correspondence and offprint requests to: Laila Bruun, MD, Department of Nephrology and Transplantation, University Hospital Malmö, SE-205 02 Malmö, Sweden. Email: laila.bruun{at}klkemi.mas.lu.se


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
L. Bruun, C. Savage, A. M. Cronin, J. Hugosson, H. Lilja, and A. Christensson
Increase in percent free prostate-specific antigen in men with chronic kidney disease
Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1238 - 1241.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
J. L. Holley
Screening, Diagnosis, and Treatment of Cancer in Long-Term Dialysis Patients
Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 604 - 610.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
J. C. Routh and B. C. Leibovich
Adenocarcinoma of the Prostate: Epidemiological Trends, Screening, Diagnosis, and Surgical Management of Localized Disease
Mayo Clin. Proc., July 1, 2005; 80(7): 899 - 907.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.